MX2024002465A - Formas solidas de inhibidores de bcl-2, metodo de preparacion y sus usos. - Google Patents

Formas solidas de inhibidores de bcl-2, metodo de preparacion y sus usos.

Info

Publication number
MX2024002465A
MX2024002465A MX2024002465A MX2024002465A MX2024002465A MX 2024002465 A MX2024002465 A MX 2024002465A MX 2024002465 A MX2024002465 A MX 2024002465A MX 2024002465 A MX2024002465 A MX 2024002465A MX 2024002465 A MX2024002465 A MX 2024002465A
Authority
MX
Mexico
Prior art keywords
bcl
inhibitors
preparation
solid forms
solid form
Prior art date
Application number
MX2024002465A
Other languages
English (en)
Spanish (es)
Inventor
Yunhang Guo
Gongyin Shi
Hai Xue
Desheng Yu
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of MX2024002465A publication Critical patent/MX2024002465A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024002465A 2021-08-31 2022-08-31 Formas solidas de inhibidores de bcl-2, metodo de preparacion y sus usos. MX2024002465A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2021115718 2021-08-31
PCT/CN2022/116084 WO2023030363A1 (en) 2021-08-31 2022-08-31 Solid forms of bcl-2 inhibitors, method of preparation, and use thereof

Publications (1)

Publication Number Publication Date
MX2024002465A true MX2024002465A (es) 2024-04-29

Family

ID=85410866

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024002465A MX2024002465A (es) 2021-08-31 2022-08-31 Formas solidas de inhibidores de bcl-2, metodo de preparacion y sus usos.

Country Status (10)

Country Link
US (1) US20240317743A1 (cg-RX-API-DMAC7.html)
EP (1) EP4396180A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024530315A (cg-RX-API-DMAC7.html)
KR (1) KR20240054327A (cg-RX-API-DMAC7.html)
CN (1) CN118215660A (cg-RX-API-DMAC7.html)
AU (1) AU2022336557A1 (cg-RX-API-DMAC7.html)
CA (1) CA3230314A1 (cg-RX-API-DMAC7.html)
IL (1) IL311106A (cg-RX-API-DMAC7.html)
MX (1) MX2024002465A (cg-RX-API-DMAC7.html)
WO (1) WO2023030363A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116969937B (zh) 2020-04-15 2026-03-24 百济神州(苏州)生物科技有限公司 Bcl-2抑制剂
TW202604488A (zh) 2024-06-26 2026-02-01 瑞士商百濟神州I有限責任公司 包含索托克拉固體分散體之醫藥調配物及其製備方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2546294T7 (es) * 2009-05-26 2024-06-06 Abbvie Ireland Unlimited Co Agentes inductores de la apoptosis para el tratamiento de cáncer y enfermedades inmunitarias y autoinmunitarias
KR101762724B1 (ko) * 2011-01-25 2017-07-28 더 리젠츠 오브 더 유니버시티 오브 미시건 Bcl-2/bcl-xl 억제제 및 이를 이용한 치료 방법
CN112437772B (zh) * 2018-04-29 2023-11-21 百济神州有限公司 Bcl-2抑制剂
WO2021110102A1 (en) * 2019-12-02 2021-06-10 Beigene, Ltd. Methods of cancer treatment using bcl-2 inhibitor

Also Published As

Publication number Publication date
CA3230314A1 (en) 2023-03-09
US20240317743A1 (en) 2024-09-26
WO2023030363A1 (en) 2023-03-09
TW202328125A (zh) 2023-07-16
EP4396180A4 (en) 2025-07-09
CN118215660A (zh) 2024-06-18
EP4396180A1 (en) 2024-07-10
AU2022336557A1 (en) 2024-03-21
IL311106A (en) 2024-04-01
JP2024530315A (ja) 2024-08-16
KR20240054327A (ko) 2024-04-25

Similar Documents

Publication Publication Date Title
FI3788042T3 (fi) Bcl-2-inhibiittoreita
PH12020551870A1 (en) Tetracyclic heteroaryl compounds
EP4563150A3 (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
CO2017008862A2 (es) Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n’-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quinoxalin-6-il]etano-1,2-diamina
MX2020010999A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos.
BR112013012740A2 (pt) sais e formas cristalinas de um agente que induz apoptose
PE20160287A1 (es) Inhibidores cristalinos de bromodominos
PE20190437A1 (es) Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidin-1-carboxamida y sales del mismo
ZA202400595B (en) Spirocyclic compounds
UY29199A1 (es) Derivados tiazol, composiciones que los contienen, procedimientos de preparación y aplicaciones
AR111233A1 (es) Inhibidores de tyk2, usos y métodos para la producción de los mismos
EA201170537A1 (ru) Ингибиторы вич-интегразы
PH12023553203A1 (en) Methods of treating b-cell malignancy using bcl-2 inhibitor
CR10766A (es) Inhibidores de metaloproteasa derivados de heterociclicos
MX394644B (es) Excipiente a base de proteínas para ingredientes farmacéuticos activos.
MX2025005474A (es) Farmaco farmaceutico que contiene derivado de heterocicliden acetamida
HRP20221230T1 (hr) Farmaceutske kombinacije koje sadrže inhibitor histon deacetilaze i inhibitor bcl-2 i postupci za njihovu uporabu
MX2025000776A (es) Metodos de tratamiento del mieloma multiple con un inhibidor de bcl-2
PL3924351T3 (pl) Postać krystaliczna chlorowodorku 2-((1r,4r)-4-((3-(3-(trifluorometylo)fenylo)imidazo[1,2-b]pirydazyn-6-ylo)amino)cykloheksylo)propan-2-olu dziedzina
WO2011025683A8 (en) Hiv integrase inhibitors
JOP20170148A1 (ar) مثبطات Wnt لعلاج التليف
AR070290A1 (es) Derivados de indol-3-carboxamidas ciclicas, su preparacion, composiciones farmaceuticas que los contienen y su uso en trastornos cardiovasculares.
CL2017002180A1 (es) Formas cristalinas de un compuesto de pirrolopiridina
BR112018075823A2 (pt) sais farmacêuticos de n-(2-(2-(dimetilamino)etoxi)-4-metoxi-5-((4-(1-metil-1h-indol-3-il)pirimidin-2-il)amino)fenil)acrilamida e suas formas cristalinas
EA201270475A1 (ru) Комбинация